Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133-targeted therapies in CRC.
|
31579983 |
2020 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The in vitro evaluation in terms of cellular uptake and cytotoxicity demonstrated that the CD133-PCAD-DMSN@DOX specifically targets HT29 as a CD133 overexpressed cancer cells confirmed by flow cytometry and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay.
|
31276199 |
2020 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To detect the presence of CD133 and CD44 in human CRC specimens and to correlate the level of marker expression with tumor staging.
|
30880758 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Also, cohort evaluation showed that CD133 overexpression at protein level is a marker of poor overall survival in colorectal cancer (CRC) patients.
|
30317669 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As CD133 and CD44 are notable markers of cancer stem cells (CSCs) identity, it is thought to be a predictive indicator for colorectal cancer.
|
30799951 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer.
|
30950180 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated the co-expression and prognostic significance of the CSCs biomarkers CD44 and CD133 with wild-type EGFR (wtEGFR) and EGFRvIII in colorectal cancer (CRC).
|
30899442 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on the preclinical characterization presented in this study and the available data indicating that CD133 is broadly expressed in CRC and represents a negative prognostic marker, we conclude that 293C3-SDIE constitutes a promising therapeutic agent for the treatment of CRC and thus warrants clinical evaluation.
|
31181683 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure.
|
31619711 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The rate of CD133-positive cases in UC-CRC was significantly higher than that in dysplasia (p=0.026), but that of LGR5 expression was not.
|
31280219 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IHC detected high cytoplasmic Id1 expression in 35 CRC specimens (46.7%), and high CD133 expression in 22 CRC specimens (29.3%) and negative expression in 18 normal mucosal specimens.
|
31440083 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to evaluate prognostic significance of CD133 expression in colorectal cancer patients.A total of 303 patients with stage I to III colorectal cancer who underwent curative surgical resection from 2003 to 2008 at a single institution were included.
|
31393377 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two meta-analysis reports have suggested that CD133 expression is significantly associated with shorter survival, and CD133 may play an important role in the progression of colorectal cancer.
|
28190751 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collagen was highly deposited in the CRC invasive tumor front (ITF), and the expression of CD133 was higher in ITF compared with normal tissue and the tumor cells.
|
30218452 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed CCK8 and tumor sphere formation assays, percentage analysis of both side population and CD133+CD44+ cells, and the detection of stem cells markers, in order to assess the role of GA in inhibiting the stem celllike features of CRC.
|
29627822 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the clinicopathological and prognostic significance of CD133 in CRC patients remains controversial.
|
29879012 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, the chemoresistant CRC cell line HCT116-CSC with high expression of the stem cell markers CD44 and CD133 was established for further phenotypic tests.
|
30275459 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer.
|
29519158 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ABC member B5 (ABCB5) mediates multidrug resistance (MDR) in diverse malignancies and confers clinically relevant 5-fluorouracil resistance to CD133-expressing cancer stem cells in human colorectal cancer (CRC).
|
29789423 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Proficient MMR correlated with high levels of CD133-marked putative cancer stem cells in both right- and left-sided tumors, whereas significantly lower levels of CD133-marked putative cancer stem cells were associated with deficient MMR status in colorectal carcinomas found on the right.
|
30221090 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared to control, the expression of CD133 and ezrin mRNA and protein in CRC were significantly up-regulated (P < 0.05).
|
28261953 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To accomplish this aim, we use immunohistochemistry (IHC) and double IHC with different potential stem-like markers, anti-musashi (Msi), anti-CD133, anti- LGR5 and anti-ALDH1 to examine the presentation of stem-like cells in different compartments including adenoma/CRC epithelium, transitional crypts and tumor stroma in colorectal adenoma and CRC.
|
28484082 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 (Prominin-1) is an important cell surface marker of cancer stem (like) cells (CSCs) in various cancers, including CRC.
|
29100290 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings suggest that CD133 could serve as a predictive marker of poor prognosis and treatment failure in CRC.
|
26840260 |
2016 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the current research, CD133 expression in primary CRC was detected by immunohistochemistry, and an asymmetric BiAb consisting of monomer of chimeric AC133 (mouse anti-human CD133 monoclonal antibody) and single chain of humanized OKT3 was developed to eradicate CD133-expressing tumor cells by arming activated T cells in vitro and in vivo.
|
26049545 |
2016 |